TYTakehiro Yasukawa

Takehiro Yasukawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takehiro Yasukawa has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Dongchon Kang

    Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka-shi, Japan

    9 shared publications
  • Shigeru Matsuda

    Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka-shi, Japan

    6 shared publications
  • Akira Orimo

    Department of Pathology and Oncology Juntendo University Faculty of Medicine Tokyo Japan

    3 shared publications
  • Kazuto Nakada

    Institute of Life and Environmental Sciences, University of Tsukuba, Tsukuba-shi, Japan

    3 shared publications
  • Yura Do

    Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka-shi, Japan

    3 shared publications
  • Akane Ishizuka

    Department of Molecular Pathogenesis Juntendo University Graduate School of Medicine Tokyo Japan

    2 shared publications

Latest Publications

  • Hepatoprotective Effects of Imeglimin Are Associated With Preserved Mitochondrial Bioenergetics and Reduced Oxidative Stress in a Murine Cholestasis Model

    by Hiroki Goto, Kazuto Suda, Takehiro Yasukawa, Takashi Fujimoto, Xuxuan Rao, Yosuke Tsunoda, Masataka Hida, Meng Xia, Chengri Piao, Jianqin Zhang, et al.

    Purpose: Biliary atresia is a cholestatic liver disease that causes persistent inflammation and reduces the hepatic reserve. New therapeutic concepts are crucial to improve native liver survival. We investigated whether imeglimin, a mitochondria‐targeting agent, has hepatoprotective effects on cholestatic liver disease using a murine bile duct ligation (BDL) model. Methods: BDL was performed in 4–5‐week‐old mice. After BDL, the mice received intraperitoneal imeglimin or vehicle injections. Sham‐operated mice received vehicle. Blood and liver samples were collected on days 7 and 14 for biochemical and histological analysis. Mitochondrial morphology was examined by transmission electron microscopy. Quantitative PCR and immunoblotting were performed for inflammation and mitochondrial stress markers. Metabolomic profiling was conducted using capillary electrophoresis–mass spectrometry. Transcriptome was analyzed by RNA sequencing. Seahorse assays, ATP quantification, and MitoSOX staining were used to evaluate mitochondrial function and oxidative stress. Results: Imeglimin improved survival after BDL, and reduced serum AST, ALT, and bilirubin levels. Tissue fibrosis and Col1a1 and Acta2 expression were attenuated in imeglimin‐treated livers. Glycolysis, amino acid metabolism, and mitochondrial electron transport activity were enhanced. Expression of genes associated with mitochondrial function, antioxidant defense, and metabolic regulation was upregulated. Mitochondrial morphology was preserved, and mitochondrial number and size increased. Imeglimin elevated oxygen consumption, extracellular acidification rates, and ATP levels of BDL mice livers, while reducing mitochondrial superoxide and oxidative protein modification by 4‐hydroxynonenal. Expression levels of Il1β , Il6 , and Tnf decreased. Conclusion: Imeglimin exerted hepatoprotective effects on BDL‐operated mice, which are associated with preserved mitochondrial bioenergetic function and reduced oxidative stress.


  • Open Access

    TEFM facilitates transition from RNA synthesis to DNA synthesis at H-strand replication origin of mtDNA

    by Shigeru Matsuda, Masunari Nakayama, Yura Do, Takashi Ishiuchi, Mikako Yagi, Sjoerd Wanrooij, Kazuto Nakada, Fan-Yan Wei, Kenji Ichiyanagi, Hiroyuki Sasaki, et al.

    Transcription of human mitochondrial DNA (mtDNA) begins from specific transcription promoters. In strand-asynchronous mtDNA replication, transcripts from the light-strand promoter serve as primers for leading-strand synthesis at the origin of the H-strand replication (OH). A 7S DNA strand, a presumed aborted replication product, is also synthesized from OH. Transition from RNA synthesis to DNA synthesis at OH is crucial for balancing replication with transcription, yet the mechanism remains unclear. Herein, we examine the role of mitochondrial transcription elongation factor (TEFM) in this process. TEFM knockout results in decreased 7S DNA, strand-asynchronous replication intermediates, and mtDNA copy number, all of which are concordant with downregulation of RNA-to-DNA transition at OH. Conversely, levels of tRNAs encoded near transcription promoters increase, indicating enhanced transcription initiation frequency. Taken together, we propose that, in addition to conferring processivity to the mitochondrial RNA polymerase, TEFM plays a crucial role in maintaining the balance between mitochondrial transcription and replication.


  • Open Access

    Expression of Lymphoid Enhancer‐Binding Factor 1 in Cancer‐Associated Fibroblasts Mediates Tumor Growth and Transdifferentiation Toward Squamous Cell Carcinoma in Human Breast Cancer

    by Hiroya Okazaki, Yoshihiro Mezawa, Yang Shi, Mizuki Sakimoto, Zixu Wang, Akane Ishizuka, Kazunari Yamashita, Asahi Satoh, Yu Koyama, Yuki Fukumura, et al.

    Background: Cancer‐associated fibroblasts (CAFs) play a significant role in human breast cancer as a major stromal component. While their role in promoting cancer proliferation and malignancy through interaction with cancer cells in the tumor microenvironment is known, the exact mechanisms behind this interaction are not fully understood.Results: Our study reveals that lymphoid enhancer‐binding factor 1 (LEF1), a central transcription factor for Wnt/β‐catenin signaling, is expressed in experimentally generated tumor‐promoting CAFs (exp‐CAFs) as well as in CAFs from breast cancer patients, particularly those with a poor prognosis. Notably, LEF1‐expressing CAFs are prevalent in the stroma of squamous cell carcinoma (SCC), an aggressive metaplastic breast cancer subtype with a limited understanding of its development. To investigate the functional importance of LEF1 expression in CAFs, we depleted LEF1 in the exp‐CAFs and subcutaneously implanted them along with breast ductal carcinoma MCF10DCIS.com cells into immunodeficient mice. Depleting LEF1 resulted in reduced xenograft tumor growth, accompanied by decreased cancer‐cell proliferation and angiogenesis in the tumors. Additionally, we observed a significant reduction in the expression of SCC markers p40 (ΔNp63) and cytokeratin 5/6 in the xenograft tumors when LEF1 was depleted in the exp‐CAFs. Furthermore, we identified 13 genes, none of which are established downstream genes of the Wnt/β‐catenin pathway, that exhibit expression patterns similar to LFE1 in our cultured fibroblasts.Conclusion: In summary, our findings suggest that LEF1 expression contributes to the tumor‐promoting abilities of breast CAFs and that LEF1‐expressing CAFs may drive transdifferentiation toward SCC, possibly through a pathway independent of the canonical Wnt/β‐catenin signaling.

  • Open Access

    Association of stromal type IV collagen and prognosis in neoadjuvant chemotherapy-treated pancreatic cancer

    by Yasuhiro Nakamura, Takehiro Yasukawa, Yuki Fukumura, Yoshinori Takeda, Hiroshi Imamura, Yang Shi, Mu Li, Masaaki Abe, Saya Uyama, Kazunori Kajino, et al.

    Background: Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to its low surgical eligibility and resistance to chemotherapy. Abundant stroma is characteristic of PDAC, and cancer-associated fibroblasts (CAFs) are a major stromal constituent, contributing to chemoresistance. Because neoadjuvant chemotherapy (NAC) is included in PDAC treatment as a standard regimen, the role of CAFs in NAC resistance must be studied. Although type IV collagen (COLIV) is present in the tumor of PDAC, the association between COLIV and disease advancement of NAC-treated PDAC is unclear. Methods: Using a cohort of NAC-treated patients with PDAC, we examined clinicopathological data and conducted immunohistochemical analysis of COLIV in tissue specimens prepared from surgically resected pancreas. Results and Conclusions: Our analysis revealed that ~50% of the cases were positive for COLIV in the stroma and diffuse COLIV staining was an independent poor prognosis factor alongside high serum CA19-9 before NAC treatment (>37 U/mL) and postsurgical residual tumors. Based on these findings, we propose that stromal COLIV staining can be used to predict prognosis in NAC-treated patients with PDAC after surgery. Additionally, these findings suggest a possibility that stromal COLIV staining indicates resistance to anticancer drugs and/or contributes to malignancy in PDAC.


  • Open Access

    Increased RUNX3 expression mediates tumor‐promoting ability of human breast cancer‐associated fibroblasts

    by Yu Koyama, Hiroya Okazaki, Yang Shi, Yoshihiro Mezawa, Zixu Wang, Mizuki Sakimoto, Akane Ishizuka, Yasuhiko Ito, Takumi Koyama, Yataro Daigo, et al.

    Background: Cancer‐associated fibroblasts (CAFs) are a major stromal component of human breast cancers and often promote tumor proliferation, progression and malignancy. We previously established an experimental CAF (exp‐CAF) cell line equipped with a potent tumor‐promoting ability. It was generated through prolonged incubation of immortalized human mammary fibroblasts with human breast cancer cells in a tumor xenograft mouse model.Results: Herein, we found that the exp‐CAFs highly express Runt‐related transcription factor 3 (RUNX3), while counterpart fibroblasts do not. In breast cancer patients, the proportion of RUNX3‐positive stromal fibroblast‐like cells tends to be higher in cancerous regions than in non‐cancerous regions. These findings suggest an association of RUNX3 with CAF characteristics in human breast cancers. To investigate the functional role of RUNX3 in CAFs, the exp‐CAFs with or without shRNA‐directed knockdown of RUNX3 were implanted with breast cancer cells subcutaneously in immunodeficient mice. Comparison of the resulting xenograft tumors revealed that tumor growth was significantly attenuated when RUNX3 expression was suppressed in the fibroblasts. Consistently, Ki‐67 and CD31 immunohistochemical staining of the tumor sections indicated reduction of cancer cell proliferation and microvessel formation in the tumors formed with the RUNX3‐suppressed exp‐CAFs.Conclusion: These results suggest that increased RUNX3 expression could contribute to the tumor‐promoting ability of CAFs through mediating cancer cell growth and neoangiogenesis in human breast tumors.


  • Assessing TFAM Binding to Human Mitochondrial DNA

    by Takehiro Yasukawa, Dongchon Kang

    Mitochondrial transcription factor A (TFAM) is a mitochondrial DNA (mtDNA)-binding protein that plays a crucial dual role in the initiation of mitochondrial transcription initiation and mtDNA maintenance. Because TFAM directly interacts with mtDNA, assessing its DNA-binding property can provide useful information. This chapter describes two in vitro assay methods, an electrophoretic mobility shift assay (EMSA) and a DNA-unwinding assay with recombinant TFAM proteins, which both require simple agarose gel electrophoresis. These are used to investigate the effects of mutations, truncation, and posttranslational modifications on this key mtDNA regulatory protein. Key words Mitochondrial transcription factor A TFAM Mitochondrial DNA mtDNA Mitochondrial nucleoids Electrophoretic mobility shift assay EMSA DNA-unwinding assay


  • Open Access

    Aberrant RNA processing contributes to the pathogenesis of mitochondrial diseases in trans-mitochondrial mouse model carrying mitochondrial tRNALeu(UUR) with a pathogenic A2748G mutation

    by Haruna Tani, Kaori Ishikawa, Hiroaki Tamashiro, Emi Ogasawara, Takehiro Yasukawa, Shigeru Matsuda, Akinori Shimizu, Dongchon Kang, Jun-Ichi Hayashi, Fan-Yan Wei, et al.

    Mitochondrial tRNAs are indispensable for the intra-mitochondrial translation of genes related to respiratory subunits, and mutations in mitochondrial tRNA genes have been identified in various disease patients. However, the molecular mechanism underlying pathogenesis remains unclear due to the lack of animal models. Here, we established a mouse model, designated ‘mito-mice tRNALeu(UUR)2748’, that carries a pathogenic A2748G mutation in the tRNALeu(UUR) gene of mitochondrial DNA (mtDNA). The A2748G mutation is orthologous to the human A3302G mutation found in patients with mitochondrial diseases and diabetes. A2748G mtDNA was maternally inherited, equally distributed among tissues in individual mice, and its abundance did not change with age. At the molecular level, A2748G mutation is associated with aberrant processing of precursor mRNA containing tRNALeu(UUR) and mt-ND1, leading to a marked decrease in the steady-levels of ND1 protein and Complex I activity in tissues. Mito-mice tRNALeu(UUR)2748 with ≥50% A2748G mtDNA exhibited age-dependent metabolic defects including hyperglycemia, insulin insensitivity, and hepatic steatosis, resembling symptoms of patients carrying the A3302G mutation. This work demonstrates a valuable mouse model with an inheritable pathological A2748G mutation in mt-tRNALeu(UUR) that shows metabolic syndrome-like phenotypes at high heteroplasmy level. Furthermore, our findings provide molecular basis for understanding A3302G mutation-mediated mitochondrial disorders.


  • TFB2M and POLRMT are essential for mammalian mitochondrial DNA replication

    by Teppei Inatomi, Shigeru Matsuda, Takashi Ishiuchi, Yura Do, Masunari Nakayama, Shusaku Abe, Kazutoshi Kasho, Sjoerd Wanrooij, Kazuto Nakada, Kenji Ichiyanagi, et al.


  • Open Access

    Catalytically inactive Cas9 impairs DNA replication fork progression to induce focal genomic instability

    by Goro Doi, Satoshi Okada, Takehiro Yasukawa, Yuki Sugiyama, Siqin Bala, Shintaro Miyazaki, Dongchon Kang, Takashi Ito

    Catalytically inactive Cas9 (dCas9) has become an increasingly popular tool for targeted gene activation/inactivation, live-cell imaging, and base editing. While dCas9 was reported to induce base substitutions and indels, it has not been associated with structural variations. Here, we show that dCas9 impedes replication fork progression to destabilize tandem repeats in budding yeast. When targeted to the CUP1 array comprising ∼16 repeat units, dCas9 induced its contraction in most cells, especially in the presence of nicotinamide. Replication intermediate analysis demonstrated replication fork stalling in the vicinity of dCas9-bound sites. Genetic analysis indicated that while destabilization is counteracted by the replisome progression complex components Ctf4 and Mrc1 and the accessory helicase Rrm3, it involves single-strand annealing by the recombination proteins Rad52 and Rad59. Although dCas9-mediated replication fork stalling is a potential risk in conventional applications, it may serve as a novel tool for both mechanistic studies and manipulation of genomic instability.